-
Product Name
Pinatuzumab vedotin reference antibody
- Documents
-
Description
Anti-Siglec-2 / CD22 Antibody (Pinatuzumab vedotin)
-
Tested applications
ELISA
-
Species reactivity
Human Siglec-2 / CD22
-
Isotype
IgG1
-
Preparation
Recombinant expression and purified from CHO cells.
-
Clonality
Monoclonal
-
Formulation
0.1 M Pro-Ac, 20 mM Arg, pH 5.0
-
Storage instructions
-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.
-
Validations
SDS-PAGE
Anti-Siglec-2 / CD22 Antibody (pinatuzumab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.
SEC-HPLC
The purity of Anti-Siglec-2 / CD22 Antibody (pinatuzumab vedotin) is more than 95%, determined by SEC-HPLC.
HIC-HPLC
The drug-to-antibody ratio (DAR) of the Anti-Siglec-2 / CD22 Antibody (Pinatuzumab vedotin) is 4.3.
Bioactivity: ELISA
Immobilized human Siglec 2 / CD22, His Tag at 2 ug/mL can bind Anti-Siglec-2 / CD22 Antibody (Pinatuzumab vedotin), EC50=0.008851 ug/mL.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"